

INTERNATIONAL MESOTHELIOMA INTEREST GROUP
FOURTH INTERNATIONAL MESOTHELIOMA CONFERENCE
PHILADELPHIA, PA
PENN TOWER HOTEL (34TH AND CIVIC CENTER BLVD)
MAY 13-15, 1997

TUESDAY MAY 13, 1997

08:15-09:00 Registration and Continental Breakfast

WELCOMING STATEMENTS

09:00-09:10 Dr P. Chahinian (New York, NY)

09:10-09:20 Dr J. Glick (Philadelphia, PA)

Symposium I: BIOLOGY/CARCINOGENESIS

Chair: Dr. M.-C. Jaurand (Créteil, France), Dr. Brenda Gerwin (Bethesda, USA)

09:20-09:35 Dr J. Bignon (Paris, FRANCE) Historical Overview

09:35-09:55 Dr A. Buard (Créteil, France) "Activation of the JAK/STAT signalling pathway in IFN- γ -treated human mesothelioma cell lines" **B1**

09:55-10:15 Dr S. Faux (Burlington, VT) "Involvement of Ca²⁺ in *c-fos* and transcription factor induction by crocidolite asbestos in rat pleural mesothelial (RPM) cells" **B2**

10:15-10:35 Dr P. Ferriola (Research Triangle Park, NC) "Alterations in expression of Bcl2 family genes by fibrous particulates in pleural mesothelial cells" **B3**

10:35-10:50 Coffee Break

10:50-11:10 Dr K. Dobra (Huddinge, Sweden) "Proteoglycan synthesis by epithelial and fibrous mesothelioma cells" **B4**

11:10-11:30 Dr F. Hervé (Créteil, France) "Study of the microheterogeneity of α 1-acid glycoprotein and its genetic variants in malignant mesothelioma" **B5**

11:30-11:45 General Discussion

11:45-14:00 LUNCH and POSTER VIEWING

14:00-14:20 Dr S. Mutsaers (London, UK) "Malignant mesothelioma cells produce higher levels of procollagen than normal mesothelial cells *in vitro*, and are further stimulated by TGF- β 1" **B6**

14:20-14:40 Dr R. Warn (Norwich, UK) "Effects of hepatocyte growth factor/scatter factor and ECM constituents on the spread and motility of mesothelioma cells in culture." **B7**

14:40-15:00 Dr S Mutsaers (London, UK) "Hepatocyte growth factor/ scatter factor stimulates mesothelial cell migration and proliferation by an autocrine mechanism." **B8**

15:00-15:20 Dr P. Harvey (Norwich, UK) "Hepatocyte growth factor/ scatter factor and its receptor, MET, in human malignant mesotheliomas. Possible roles in pathogenesis." **B9**

15:20-15:40 COFFEE BREAK

15:40-16:00 Dr J.-B. Prins (Rotterdam, THE NETHERLANDS) "Binding of nuclear factors to the platelet-derived growth factor B chain gene promoter in malignant mesothelioma." **B10**

16:00-17:00 GENERAL DISCUSSION and POSTER REVIEW

Posters:

Dr K. Takabe (Kanagawa, JAPAN) "Mineral fiber content in pleural plaques of patients with malignant mesothelioma" **BP1**

Dr A. Sahu (Lucknow, INDIA) "Responses of the pleura induced by amosite asbestos and preventive strategy" **BP2**

Dr L.N. Pylev (Moscow, RUSSIA) "Changes of rat mesothelial cell properties in processes of spontaneous and asbestos-induced transformation in culture" **BP3**

Dr L.N. Pylev (Moscow, RUSSIA) "Pathogenesis of experimental pleural mesothelioma" **BP4**

Dr S. Kumar-Singh (Antwerp, BELGIUM) "Malignant mesothelioma cell lines over express vascular endothelial growth factor and basic endothelial growth factor." **BP5**

Dr S. Kumar-Singh (Antwerp, BELGIUM) "BFGF has a prognostic value in malignant mesothelioma." **BP6**

17:00-18:00 **Cocktail Reception**

WEDNESDAY MAY 14, 1997

08:00-08:30 Registration and Continental Breakfast

08:30-10:15 Symposium: IMMUNOLOGY

Chair: Dr B. Robinson (Perth, Australia)

08:30-08:45 Dr L. Caminschi (Perth, Australia) "Systemic, intratumoral and paracrine delivery of IL-12 prevents or delays the onset of murine malignant mesothelioma" **I1**

08:45-08:55 Dr E. Kang (Philadelphia, USA) "Lack of correlation between stage of mesothelioma and ability to mount an immune response" **I3**

08:55-09:05 Dr A. Marzo (Perth, Australia) "Blockade of tumor-derived TGF- β in vivo using antisense oligonucleotides" **I4**

09:05-09:20 Dr L. Mutti (Veruno, Italy) "Mesothelioma cells can present recall antigens in vitro to autologous blood CD4+ lymphocytes" **I5**

09:20-09:35 Dr C. Porta (Veruno, Italy) "IL2 can affect directly the growth of mesothelioma cells" **I6**

09:35-10:00 Discussion

10:00-10:15 Coffee Break

10:15-12:30 Symposium: GENETICS/SV40

Chair: Dr M. Carbone (Chicago, USA), Dr J. Testa (Philadelphia, USA)

10:15-10:30 Dr A. Kane (Providence, USA) "Increased sensitivity of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers" **G1**

10:30-10:45 Dr J. Cheng (Philadelphia, USA) "Frequent alterations of NF2 and deletion of chromosome 22q12 in malignant mesothelioma. Evidence for a two-hit mechanism of NF2 inactivation" **G2**

10:45-11:00 Dr A. Boylan (Charleston, USA) "Differential expression of three novel genes in mesothelioma cells" **G3**

11:00-11:15 Dr D. Bell (Philadelphia, USA) "Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma" **G4**

11:15-11:25 Discussion

11:25-11:40 Dr P. Rizzo (Chicago, USA) "Simian virus 40-like (SV40) sequences in human malignant mesothelioma" **S1**

11:40-11:55 Dr A. Giordano (Philadelphia, USA) "The retinoblastoma family and simian virus-40 large T antigen interact in human mesotheliomas" **S2**

11:55-12:10 Dr K. Linnainmaa (Helsinki, Finland) "SV40 virus DNA sequences are not present in the tumor tissue of Finnish mesothelioma patients" **S3**

12:10-12:30 Discussion

12:30-13:30 LUNCH AND POSTER VIEWING

13:30-15:00 Symposium: PATHOLOGY

Chair: Dr J. Bignon (Creteil, France), Dr A. Hjerpe (Huddinge, Sweden)

13:30-13:40 Dr A. Hjerpe (Huddinge, Sweden) "Optimisation of a battery of 9 antibodies for the differentiation between epithelial mesothelioma and adenocarcinoma" **P1**

13:40-13:50 Dr M. Fleming (Baltimore, USA) "Desmoplastic mesothelioma (DM) is distinguishable from chronic fibrosing pleuritis (CFP) by specific cytologic, histologic, and immunohistochemical (IHC) criteria" **P2**

13:50-14:00 Dr A. Peralta Soler (Wynnewood, USA) "Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues" **P3**

14:00-14:10 Dr M. Kitagawa (Toyama, Japan) "Mesotheliomas in Japan. Pathology panels reports" **P4**

14:10-14:20 Dr A. Donna (Alessandria, Italy) "AMAD-2 and calretinin. Evaluation of their immunoreactivity with malignant mesothelioma and mesothelial hyperplasia" **P5**

14:20-14:30 Dr P. Heldin (Uppsala, Sweden) "Hyaluronan. Studies on the mechanism of biosynthesis and of interactions with hyaladherins on human mesothelial and malignant mesothelioma cells" **P6**

14:30-14:40 Dr J. Roboz (New York, USA). "Protein-bound serum hyaluronic acid (HA) in mesothelioma and models to study its formation and stepwise decomposition" **P7**

14:40-15:00 General Discussion and Poster Review - Coffee break

Posters:

Dr N. Togawa (Hyogo, Japan) "Clinical evaluation of soluble CD44 levels in patients with malignant mesothelioma" **IP1**

Dr M. Shinjo (Hyogo, Japan) "TPA and CYFRA21-1 in patients with malignant mesothelioma" **IP2**

15:00-17:00 Symposium: EPIDEMIOLOGY

Chair: Dr. William Musk (Perth, Australia)

Speakers:

15:00-15:20 Dr W. Musk (Perth, Australia) "The incidence of malignant mesothelioma after occupational and environmental exposure to Western Australian crocidolite." **E1**

15:20-15:40 Dr A. Karjalainen (Helsinki, Finland) "Mesothelioma in Finland in 1960-95" **E2**

15:40-16:05 Dr E. Ilgren (Bryn Mawr, USA) " 'Best evidence' analysis of the mesothelioma and lung cancer cases in the Libby vermiculite miners and millers." **E3**

"Preliminary analysis of the Coalinga chrysotile miners and millers and summary of final data from long term inhalational bioassays of rodents exposed to Coalinga chrysotile." **E4**

16:05-16:20 Dr M. Camus (Westmount, Canada) "Risk assessment for women living in chrysotile mining towns. 1: Environmental exposure assessment." **E5**

16:20-16:40 Dr B. Case (Westmount, Canada) "(Westmount, Canada) "Risk assessment for women living in chrysotile mining towns. 2: Mesothelioma: observed vs. predicted. " **E6**

General Discussion and Poster Review

THURSDAY MAY 15, 1997

08:30-09:00 Registration and Continental Breakfast

Plenary Session

09:00-15:00 Symposium: CLINICAL STUDIES

Chair: Dr C. Boutin (Marseille, France), Dr P. Chahinian
(New York, USA), Dr Harvey Pass (Detroit, USA)

Speakers:

09:00-09:30 Dr A. Knuutila (Helsinki, Finland) "Radiological evaluation criteria for malignant pleural mesothelioma. Comparison of CT and MRI" **C1**

09:30-10:00 Dr L. Tammilehto (Helsinki, Finland) "Factors affecting surgical strategies in patients with malignant pleural mesothelioma" **C2**

10:00-10:20 Dr P. Baas (Amsterdam, The Netherlands) "Photodynamic therapy with m-THPC as adjuvant treatment for resected malignant mesothelioma." **C3**

10:20-10:30 Coffee break

10:30-10:45 Dr L. Robinson (Tampa, USA) "Induction chemotherapy in pleural mesothelioma precludes the technical performance of an extrapleural pneumonectomy" **C4**

10:45-11:00 Dr C. Boutin (Marseille, France) "Malignant pleural mesothelioma. Results of a Phase II trial of combined chemotherapy" **C5**

11:00-11:15 Dr P. Ruffié (Villejuif, France) "Phase II study of paclitaxel (Taxol) and cisplatin (CDDP) in advanced pleural malignant mesothelioma (MM)" **C6**

11:15-11:30 Dr T. Nakano (Hyogo, Japan) "A pilot Phase II study of irinotecan (CPT-11) in combination with cisplatin administered intravenously to patients with malignant mesothelioma" **C7**

11:30-11:45 Dr B. Castagneto (Torino, Italy) "Intracavitary and systemic rIL-2 in the treatment of malignant pleural mesothelioma" **C8**

11:45-12:00 Discussion

12:00-13:30 LUNCH AND POSTER VIEWING

13:30-14:00 Poster Review and General Discussion

14:00-17:00 Symposium: GENE THERAPY

Chairs: Dr S. Albelda (Philadelphia, USA), Dr L. Kaiser (Philadelphia, USA)

Speakers:

14:00-14:15 Dr S. Albelda "General Approaches to Cancer Gene Therapy"

14:15-14:30 Dr. Bruce Robinson (Perth, Australia) "Immunologic approaches to Gene Therapy"

14:30-14:50 Dr D. Sterman (Philadelphia, USA) "Adenoviral mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy for malignant pleural mesothelioma. Results of a Phase I clinical trial" **GT1**

14:50-15:10 Dr B. Robinson (Perth, Australia) "Intralesional vaccinia virus-interleukin 2 (VV-IL2) gene therapy in malignant mesothelioma (MM)" **GT2**

15:10-15:30 Dr K. Molnar-Kimber (Philadelphia, USA) "Adenoviral-based gene therapy for patients with localized mesothelioma. Induced cellular and humoral immune response" **GT3**

15:30-15:50 Coffee Break

15:50-16:05 Dr K. Gelfand (Philadelphia, USA) "Mesothelioma patients administered recombinant adenoviral-based gene therapy intrapleurally exhibit TH1 cellular immune response" **GT4**

16:05-16:20 Dr N. Rizk (Philadelphia, USA) "Evaluation of the bystander effect in adenovirus mediated p53 gene therapy" **GT6**

16:20-16:40: Dr. Larry R. Kaiser (Philadelphia, USA) "Gene Therapy- New Directions"

16:40-17:00 General Discussion

THURSDAY MAY 15, 1997 Poster Sessions

CLINICAL STUDIES - GENE THERAPY

09:00-17:00

Dr A. Zaccaria (Trieste, Italy): "Malignant pleural mesothelioma. Prognostic factors" **CP1**

Dr A. Tonomura (Hyogo, Japan): "Immunotherapy using streptococcal preparation OK-432 for the treatment of malignant mesothelioma. A preliminary study" **CP2**

Dr S. Mikulski (Bloomfield, USA): "The use of Onconase (ONC) for patients (PTS) with advanced malignant mesothelioma (MM)" **CP3**

Dr M. Lopez (Paris, France): "Local adoptive immunotherapy using IFN γ -activated autologous macrophages in malignant pleural mesothelioma. A phase I/II study." **CP4**

Dr K. Linnainmaa (Helsinki, Finland): "Individual variation in response to cytostatic chemotherapy in the treatment of mesothelioma. In vitro studies in human cell lines." **CP5**

Dr L. Coonrod (Philadelphia, USA): "Retinoids augment the bystander effect in HSVtk/GCV mediated gene therapy by enhanced gap junctional intercellular communication." **CP6**